MA51283A - Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho - Google Patents

Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho

Info

Publication number
MA51283A
MA51283A MA051283A MA51283A MA51283A MA 51283 A MA51283 A MA 51283A MA 051283 A MA051283 A MA 051283A MA 51283 A MA51283 A MA 51283A MA 51283 A MA51283 A MA 51283A
Authority
MA
Morocco
Prior art keywords
tyrosine derivatives
rho inhibitors
kinase
kinase rho
inhibitors
Prior art date
Application number
MA051283A
Other languages
English (en)
Inventor
Alessandro Accetta
Gurdip Bhalay
Christine Edwards
Fabio Rancati
Patrizia Tisselli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA51283A publication Critical patent/MA51283A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA051283A 2017-12-18 2018-12-12 Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho MA51283A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17208186 2017-12-18

Publications (1)

Publication Number Publication Date
MA51283A true MA51283A (fr) 2021-05-26

Family

ID=60673852

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051283A MA51283A (fr) 2017-12-18 2018-12-12 Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho

Country Status (4)

Country Link
US (1) US11725007B2 (fr)
EP (1) EP3728246B1 (fr)
MA (1) MA51283A (fr)
WO (1) WO2019121223A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230121812A (ko) 2020-12-15 2023-08-21 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 다이하이드로퓨로피리딘 유도체
KR20230121811A (ko) 2020-12-15 2023-08-21 키에시 파르마슈티시 엣스. 피. 에이. Rho-키나아제 억제제로서 다이하이드로퓨로피리딘 유도체
MX2023005867A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de la cinasa rho.
WO2023110700A1 (fr) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dérivés de dihydrofuropyridine utilisés comme inhibiteurs de la rho-kinase

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003278088A1 (en) 2002-10-28 2004-05-25 Bayer Healthcare Ag Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
DE102004017438A1 (de) 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
WO2006009889A1 (fr) 2004-06-17 2006-01-26 Smithkline Beecham Corporation Inhibiteurs novateurs de protéines rho-kinases
CA2709918A1 (fr) 2007-12-21 2009-06-25 The Scripps Research Institute Benzopyranes et analogues utilises comme inhibiteurs de la rho kinase
CN102159547A (zh) 2008-09-18 2011-08-17 安斯泰来制药株式会社 杂环甲酰胺化合物
MA34373B1 (fr) 2010-07-14 2013-07-03 Novartis Ag Composés hétérocycliques agonistes du récepteur ip
SI2951172T1 (sl) 2013-01-29 2017-08-31 Redx Pharma Plc Piridin derivati kot inhibitorji mehkih kamnov
TWI800498B (zh) 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
CA3047212A1 (fr) 2017-01-30 2018-08-02 Chiesi Farmaceutici S.P.A. Derives de tyrosine amide utilises en tant qu'inhibiteurs de la rho-kinase

Also Published As

Publication number Publication date
EP3728246B1 (fr) 2021-09-22
WO2019121223A1 (fr) 2019-06-27
US20200377500A1 (en) 2020-12-03
EP3728246A1 (fr) 2020-10-28
US11725007B2 (en) 2023-08-15

Similar Documents

Publication Publication Date Title
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA46339A (fr) Dérivés de cyanopyrrolidine ayant une activité en tant qu'inhibiteurs de l'usp 30
MA52486A (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA47013A (fr) Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
EP3853220A4 (fr) Dérivés de quinazoline en tant qu'agents antitumoraux
FR25C1047I1 (fr) Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase
EP3733671A4 (fr) Dérivés amino-fluoropipéridines utilisés en tant qu'inhibiteur de kinase
MA51431A (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
EP3478687A4 (fr) Dérivés de pyrazolopyrimidine comme inhibiteurs de kinase
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
MA47086A (fr) Dérivés de dihydropyrimidine-carboxamide bicycliques utilisés en tant qu'inhibiteurs de rho-kinase
ME03404B (fr) Dérivés d'amides polycycliques comme inhibiteurs de la cdk9
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA53110A (fr) Composés polycycliques en tant qu'inhibiteurs de la tyrosine-kinase de bruton
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
MA50013A (fr) Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton